



# Respiratory Syncytial Virus (RSV) Products Order Form

### FAX COMPLETED FORM TO 905-465-3403

PHU Use Only

A temperature log with 30 most recent days must be included with the order if your facility has not ordered other vaccines within the same ordering cycle using the <u>online vaccine ordering system</u>.

Order No.:

### **Section 1: Facility Information**

Facility Name			Holding Point Code HAL OK 00		Date				
Facility Contact									
Last Name			First Name	}					
Telephone No.			Fax No.		Email Address				
Facility Address									
Unit #	Street #	Street Name		City/Town	Province	Postal Code			
Requested Delivery Method Orders will be distributed according to the current Vaccine Distribution Schedule*									
				1					
□ Pick-up Tuesday □ Pick-up Wedr		esday Delivery (only for facilities with existing courier arrangeme		er arrangements)					

## Section 2: Product and Eligibility Criteria

## **RSV Prevention Program for Infants and High-Risk Children** Refer to the Ministry of Health for program eligibility details **PRODUCT INDICATION** # OF # OF **DOSES ON** DOSES **HAND** REQUIRED Beyfortus® 50mg Infants < 5kg (Nirsevimab) Beyfortus® 100mg Infants and high-risk children ≥ 5kg (Nirsevimab) Abrysvo™ Pregnant individuals 32-36 weeks gestation, who will deliver during the RSV season (November -April) \*Note that Nirsevimab is preferred over Abrysvo for the prevention of RSV in infants. Refer to NACI Statement on the Prevention of RSV Disease in Infants



High-Risk Old	er Adult Program							
Refer to the Ministry of Health for program eligibility details								
PRODUCT	ELIGIBILITY CRITERIA FOR DOSES ORDERED	# OF DOSES ON HAND	# OF DOSES REQUIRED					
Arexvy / Abrysvo <sup>™</sup>	□ Resident of a Long-Term Care or Retirement Home Facility:							
	Vaccine to be administered by dialysis unit  ☐ Receiving hemodialysis or peritoneal dialysis							
	□ Patients in hospital receiving alternate level of care (ALC)							
	□ Individuals experiencing homelessness							
	□ Individuals who identify as First Nations, Inuit, or Métis							
	Vaccine to be administered by the transplant unit for patients currently under their care  □ Recipients of solid organ or hematopoietic stem cell transplants							